AtriCure Announces Pricing of Public Offering of Common Stock - Seite 2
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About AtriCure
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic
surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator Synergy Ablation System is the first and only medical
device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide,
with more than 150,000 implanted to date.
Forward-Looking Statements
This announcement contains forward-looking statements, including statements relating to AtriCure’s expectations regarding the completion, timing and size of the proposed public offering and use of
proceeds. These statements are subject to significant risks and uncertainties; actual results could differ materially from those projected and AtriCure cautions investors not to place undue
reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to market conditions and
satisfaction of customary closing conditions related to the public offering. There can be no assurance that AtriCure will be able to complete the public offering on the anticipated terms, or at
all. Risks and uncertainties relating to AtriCure and its business can be found in AtriCure’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC which contain risk
factors. Risk factors are also contained in the preliminary prospectus supplement filed with the SEC with respect to the offering on October 3, 2018 and will be contained in the final prospectus
supplement to be filed with the SEC with respect to the offering. AtriCure undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new
information, future events, changes in AtriCure’s expectations or otherwise.
Lesen Sie auch
View source version on businesswire.com: https://www.businesswire.com/news/home/20181004005859/en/